GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Shiller PE Ratio

Nephros (Nephros) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nephros Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nephros Shiller PE Ratio Historical Data

The historical data trend for Nephros's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Shiller PE Ratio Chart

Nephros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nephros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nephros's Shiller PE Ratio

For the Medical Instruments & Supplies subindustry, Nephros's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nephros's Shiller PE Ratio falls into.



Nephros Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nephros's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Nephros's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.06/129.4194*129.4194
=-0.060

Current CPI (Dec. 2023) = 129.4194.

Nephros Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.710 99.695 -2.220
201406 -1.890 100.560 -2.432
201409 -0.180 100.428 -0.232
201412 -0.360 99.070 -0.470
201503 -0.180 99.621 -0.234
201506 -0.540 100.684 -0.694
201509 -0.180 100.392 -0.232
201512 -0.180 99.792 -0.233
201603 -0.180 100.470 -0.232
201606 -0.180 101.688 -0.229
201609 -0.090 101.861 -0.114
201612 -0.090 101.863 -0.114
201703 -0.090 102.862 -0.113
201706 -0.090 103.349 -0.113
201709 -0.090 104.136 -0.112
201712 0.180 104.011 0.224
201803 -0.270 105.290 -0.332
201806 -0.100 106.317 -0.122
201809 -0.080 106.507 -0.097
201812 -0.100 105.998 -0.122
201903 -0.200 107.251 -0.241
201906 -0.140 108.070 -0.168
201909 -0.100 108.329 -0.119
201912 -0.020 108.420 -0.024
202003 -0.130 108.902 -0.154
202006 -0.190 108.767 -0.226
202009 -0.120 109.815 -0.141
202012 -0.080 109.897 -0.094
202103 -0.060 111.754 -0.069
202106 -0.120 114.631 -0.135
202109 -0.120 115.734 -0.134
202112 -0.110 117.630 -0.121
202203 -0.190 121.301 -0.203
202206 -0.110 125.017 -0.114
202209 -0.300 125.227 -0.310
202212 -0.090 125.222 -0.093
202303 -0.030 127.348 -0.030
202306 -0.040 128.729 -0.040
202309 -0.020 129.860 -0.020
202312 -0.060 129.419 -0.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nephros  (NAS:NEPH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nephros Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nephros's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros (Nephros) Business Description

Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.
Executives
Banks Robert R. Jr. director, officer: President and CEO C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel officer: Chief Financial Officer 320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo officer: Chief Marketing Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor officer: Chief Financial Officer 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp director, 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino officer: Chief Financial Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans director, officer: President and CEO C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830

Nephros (Nephros) Headlines

From GuruFocus

Nephros Second Quarter 2022 Financial Results Conference Call

By PurpleRose PurpleRose 07-27-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 06-16-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 06-26-2022

Nephros Unveils New Branding and Website

By GuruFocusNews GuruFocusNews 04-26-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 06-06-2022

Nephros Announces Results for Quarter Ended March 31, 2022

By GuruFocusNews GuruFocusNews 05-04-2022

Nephros Announces Results for Quarter Ended March 31, 2023

By sperokesalga sperokesalga 05-10-2023